
Oncology NEWS International
- Oncology NEWS International Vol 9 No 6
- Volume 9
- Issue 6
Camptosar Approved for First-Line Rx of Advanced Colon Cancer
WASHINGTON-Pharmacia & Upjohn’s Camptosar (irinotecan) has won FDA approval for use as a first-line agent in metastatic colorectal cancer, in combination with fluorouracil (5-FU) and leucovorin. [See ONI April 2000, page 3 for the ODAC review.] The agent was approved as a follow-up colorectal cancer treatment in 1996.
WASHINGTONPharmacia & Upjohns Camptosar (irinotecan) has won FDA approval for use as a first-line agent in metastatic colorectal cancer, in combination with fluorouracil (5-FU) and leucovorin. [See ONI April 2000, page 3 for the ODAC review.] The agent was approved as a follow-up colorectal cancer treatment in 1996.
The new approval is based on two clinical trials showing that Camptosar in addition to standard treatment increased median survival by about 3 months. In one phase III study of 385 previously untreated patients, median survival was 17.4 months with Camptosar vs 14.1 for those randomized to 5-FU/leucovorin alone (P = .031) (Lancet, March 25, 2000).
Articles in this issue
almost 26 years ago
Genentech Issues Warning on Herceptinalmost 26 years ago
How Physicians Can Effect Changes in Health Care Policyalmost 26 years ago
Four From Congress Receive Tsongas Awardalmost 26 years ago
NCI Targets Cancer Disparities With Community-Based Programsalmost 26 years ago
Mapping Predicts Nodal Status in Colorectal Cancer Patientsalmost 26 years ago
SSO President Tells Members: ‘Remember Your Core Values’almost 26 years ago
HHS Grants $794 Million in Ryan White Funds to Improve HIV Servicesalmost 26 years ago
Rapid Dose Titration With Controlled-Release Oxycodonealmost 26 years ago
Standard-Dose Chemo May Have Long-Term Cognitive EffectsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



















































